Stratasys Creates 3...
Health Care: Drugs
Neostem Inc. (NBS: AMEX)
$0.58 0.00 | 0.87%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -66.37M | -56.58M | -19.40M | -24.18M |
| Operating Gains/Losses | 13.65K | -278.92K | 674.76K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -554.88K | 116.79K | 98.50K | 571.69K |
| (Increase) Decrease in Inventories | -465.28K | 4.64M | -7.47M | -2.43M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.68M | -6.89M | 5.53M | 1.03M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | -1.00M | 0.00 |
| (Increase) Decrease In Other Working Capital | 2.59M | -1.80M | -127.11K | 1.75M |
| Other Non-Cash Items | 41.54M | 29.92M | 8.65M | 12.23M |
| Net Cash From Continuing Operations | -18.76M | -20.93M | -8.48M | -8.65M |
| Net Cash From Discontinued Operations | 4.91M | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -13.85M | -20.93M | -8.48M | -8.65M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 2.74M | 0.00 |
| Purchases of Property, Plant & Equipment | -531.32K | -5.91M | -16.38M | -2.39M |
| Acquisitions | 12.28M | 320.86K | 0.00 | 696.46K |
| Purchases of Short-Term Investments | 0.00 | -28.00 | -2.42M | 0.00 |
| Other Cash from Investing Activities | 0.00 | 3.53M | -1.05M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 6.09M | -2.05M | -17.11M | -1.69M |
| Issuance of Debt | 666.50K | 31.86M | 23.51M | 2.37M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 23.03M | 21.15M | 30.11M | 15.67M |
| Repayment of Long-Term Debt | -637.06K | -32.30M | -23.20M | -974.62K |
| Repurchase of Capital Stock | -5.39M | -650.00K | 0.00 | 0.00 |
| Payment of Cash Dividends | -327.75K | 0.00 | -222.92K | 0.00 |
| Other Financing Charges, Net | -228.68K | 7.10K | 3.67M | 0.00 |
| Net Cash From Financing Activities | 8.74M | 20.07M | 33.86M | 17.07M |
| Effect of Exchange Rate Changes | 14.39K | 46.24K | 180.06K | 0.00 |
| Net Change in Cash & Cash Equivalents | 992.02K | -2.87M | 8.45M | 6.73M |
Portfolios with NBS
- Portfolio NameUser Type
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserChris
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest NBS Headlines from TheStreet
- NeoStem Announces Geographic Expansion Of Intellectual Property Coverage Of Cardiovascular Asset AMR-001 05.16.13 | 07:05 am
- NeoStem To Present At Multiple Conferences In May 05.14.13 | 07:05 am
- NeoStem's Subsidiary, Progenitor Cell Therapy, To Provide Autologous And Allogeneic Cellular Therapy Services To MedStar Georgetown University Hospital 05.13.13 | 07:05 am
- NeoStem Clarification: No New Securities Being Issued 05.09.13 | 07:05 pm
- NeoStem CEO's Letter To Shareholders 05.09.13 | 04:05 pm
- NeoStem Announces Closing Of Public Offering Of Common Stock 05.03.13 | 08:05 am
- NeoStem Announces Partial Exercise Of Underwriters' Over-Allotment Option 04.30.13 | 06:04 pm
- NeoStem Announces Pricing Of Public Offering Of Common Stock 04.29.13 | 08:04 pm
- NeoStem Announces Proposed Public Offering Of Common Stock 04.29.13 | 04:04 pm
- NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into A Services Agreement With Sentien Biotechnologies, Inc. 04.29.13 | 08:04 am
Press Releases for NBS
- Faruqi & Faruqi, LLP Launches Investigation Against NeoStem, Inc. (NBS) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors In The Manner It Seeks Executive Compensation Approval - Business Wire 09.18.12 | 04:09 pm
- Donald Trump, Jr. Headlines As Special Speaker At The WallStreet Research⢠Small Cap Conference VII, Being Held At The Penn Club (Affiliated With The Wharton School Of Finance) On November 15th - PR Newswire 11.15.11 | 07:11 am
- NeoStem Acquires Amorcyte, A Clinical Stage Cardiovascular Disease Cell Therapy Company - PR Newswire 10.17.11 | 09:10 am
- NeoStem Announces Participation In Multiple October Conferences - PR Newswire 10.04.11 | 08:10 am
- NeoStem's Subsidiary, Progenitor Cell Therapy, And ImmunoCellular Therapeutics Enter Into A Manufacturing Agreement - PR Newswire 10.03.11 | 08:10 am
- NeoStem Announces Participation In Multiple September Conferences - PR Newswire 09.08.11 | 05:09 pm
- NeoStem Announces The Receipt Of Over $1,700,000 In DOD Funding For Its VSEL⢠Technology Being Developed To Treat Osteoporosis - PR Newswire 08.08.11 | 09:08 am
- NeoStem Subsidiary, Progenitor Cell Therapy, Announces Extension Of Manufacturing Agreements With Two Existing Clients - PR Newswire 07.18.11 | 09:07 am
- NeoStem Announces The Addition Of Joseph Talamo As Vice President, Corporate Controller And Chief Accounting Officer - PR Newswire 06.30.11 | 09:06 am
- The Pontifical Council For Culture And NeoStem Announce Steps Forward In Their Partnership To Advance Adult Stem Cell Research - PR Newswire 06.16.11 | 07:06 am
Partner Headlines for NBS
- NeoStem's Progenitor Cell Therapy Announces Services Agreement with Sentien - Benzinga 04.29.13 | 08:04 am
- Gain An Innovation, Strategic Edge With Partnerships - Investor's Business Daily 04.09.13 | 02:04 pm
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Forex Flash: Sheding some light on China/HSBC PMI differences - Markit - NASDAQ 09.03.12 | 12:09 am
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- Baxter And Neostem Validating Each Other's Cell Therapies - Seeking Alpha 06.01.12 | 09:06 am
- Rodman & Renshaw Reiterates NeoStem Market Outperform, $3 PT - Benzinga 07.20.11 | 01:07 pm
